文献速递衰弱、肌少症与跌倒老年慢病共病管理

土耳其老年人群接种SARS-CoV-2灭活疫苗后的抗体反应

Antibody response with SARS-CoV-2 inactivated vaccine (CoronaVac) in Turkish geriatric population.
PubMed 文献 · Age Ageing · 2022-01-01

本研究纳入497例完成第二剂COVID-19灭活疫苗接种至少28天的老年患者,按接种后天数分为三组,评估抗体反应及相关因素。结果显示接种后28-59天、60-89天和≥90天组的血清阳性率分别为80.9%、73.2%和57.3%。在接种后28-89天组中,血清阴性者Charlson共病指数评分更高;在≥90天组中,血清阴性者衰弱患病率显著更高。

要点

  • 接种第二剂灭活疫苗后28-59天血清阳性率为80.9%,≥90天降至57.3%。
  • 接种后28-89天,血清阴性者Charlson共病指数评分更高。
  • 接种后≥90天,血清阴性者衰弱患病率显著更高。

核心结论

  • 这是首个评估土耳其老年人群接种SARS-CoV-2灭活疫苗后抗体反应的研究,并首次揭示抗体反应与衰弱的关系。
  • 随着接种后时间延长,血清阳性率下降,且共病和衰弱与抗体反应降低相关。

研究设计与样本

  • 纳入至少完成第二剂COVID-19灭活疫苗接种后第28天的个体,共497例老年患者。
  • 采用老年综合评估工具和临床衰弱量表进行评估,检测SARS-CoV-2刺突特异性IgG抗体,≥1 U/ml定义为血清阳性,<1 U/ml定义为血清阴性。
  • 按接种后第二剂天数分为三组:组1为28-59天(188例),组2为60-89天(148例),组3为≥90天(171例)。

主要发现

  • 三组血清阳性率分别为80.9%、73.2%和57.3%。
  • 组1和组2中,血清阴性组Charlson共病指数评分更高(P=0.023和P=0.011)。
  • 组3中,血清阴性组衰弱患病率显著更高(P=0.002)。

关键数值与推荐

  • SARS-CoV-2刺突特异性IgG抗体≥1 U/ml为血清阳性,<1 U/ml为血清阴性。
  • 分组依据:组1接种后28-59天,组2 60-89天,组3≥90天。

临床怎么用

  • 老年人群接种灭活疫苗后应关注抗体随时间衰减,尤其≥90天后血清阳性率明显下降。
  • 对共病负担重或衰弱的老年人,可考虑评估疫苗反应并加强免疫策略。

局限性

  • 需要更大规模研究确认抗体反应持续时间及衰弱与COVID-19疫苗反应之间的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sars-CoV-2 infection influences older individuals at the forefront, and there is still limited data on the COVID-19 vaccine response in the geriatric population. This study aimed to assess antibody response after vaccination with SARS-CoV-2 inactivated vaccine and examine possible factors affecting this response in a geriatric population. METHODS: individuals who have been on at least the 28th day after the second dose of the COVID-19 vaccine were included. Comprehensive geriatric assessment tools and the Clinical Frailty Scale were performed. SARS-CoV-2 spike-specific IgG antibodies were detected and, levels ≥1 U/ml were defined as seropositive, <1 U/ml were defined as seronegative. RESULTS: a total of 497 patients were included and divided into three groups according to the days past after the second dose of the vaccine (Group 1: 28-59 days, Group 2: 60-89 days and Group 3: 90 days and more). Groups included 188, 148 and 171 patients, respectively. Seropositivity rate in each group was 80.9,73.2 and 57.3%, respectively. In Groups 1 and 2, Charlson Comorbidity Index score was higher in the seronegative group (P = 0.023 and P = 0.011, respectively). In Group 3, the prevalence of frailty was significantly higher in the seronegative group (P = 0.002). CONCLUSION: to the best of our knowledge, this is the first study assessing the antibody response after vaccination with Sars-CoV 2 inactivated vaccine in the Turkish geriatric population. Moreover, this is the first study revealing the relationship between antibody response and frailty. Larger studies are needed to confirm the antibody response duration and the association between frailty and COVID-19 vaccine response.

来源:Age Ageing,查看原文。版权归原作者所有。

引用

  1. Okyar Baş A, Hafizoğlu M, Akbiyik F, et al. Antibody response with SARS-CoV-2 inactivated vaccine (CoronaVac) in Turkish geriatric population. Age Ageing. 2022. PMID: 35524745. doi:10.1093/ageing/afac088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。